- Market Capitalization, $K 134,037,960
- Shares Outstanding, K 2,624,593
- Annual Sales, $ 24,384 M
- Annual Income, $ 1,335 M
- 60-Month Beta 0.52
- Price/Sales 5.49
- Price/Cash Flow 16.10
- Price/Book 9.80
|Period||Period Low||Period High||Performance|
| || |
-4.26 (-7.77%)since 09/30/20
| || |
-7.35 (-12.70%)since 07/30/20
| || |
+1.52 (+3.10%)since 10/30/19
Novo Nordisk (NVO) misses earnings and sales estimates in the third quarter of 2020.
The global smart inhalers market size is set to gain impetus from the rising utilization of digital technology in the field of healthcare devices. It is aiding in increasing the efficiency of drug delivery...
, /PRNewswire/ -- The report has been added to offering.
Law Offices of Howard G. Smith announces an investigation on behalf of Innate Pharma SA ("Innate" or the "Company") (NASDAQ: IPHA) investors concerning the Company's possible violations of federal securities...
High-level results from the PONENTE Phase IIIb open-label trial showed FASENRA(R) (benralizumab) eliminated the use of maintenance oral corticosteroids (OCS) in OCS-dependent asthma patients with a broad...
, /PRNewswire/ -- As cases of infection continue to rise nationwide, has become the latest addition to the quarantine list Tuesday, bringing the total number of affected U.S. states and territories...
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)'s ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) has received acceptance for its supplemental Biologics License Application (sBLA) and has...
Astrazeneca (AZN) closed at $52.48 in the latest trading session, marking a -1.11% move from the prior day.
Investors' focus is likely to be on any update on the timeline for filing for emergency use authorization of Modena's (MRNA) coronavirus vaccine candidate on the third-quarter earrings call.
Merck (MRK) increases earnings guidance while tightening sales outlook for the year. Shares up in pre-market trading.